AKT experiences a sharp decline, raising concerns about market dynamics and institutional interest. The post AKT Plunges 6.85% — Is Institutional Interest WaningAKT experiences a sharp decline, raising concerns about market dynamics and institutional interest. The post AKT Plunges 6.85% — Is Institutional Interest Waning

AKT Plunges 6.85% — Is Institutional Interest Waning?

2026/03/07 13:30
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The crypto market just witnessed a sharp move as AKT experienced a significant decline of 6.85% over a mere 15 minutes. Currently, the AKT price sits at $0.341422, reflecting a 1.99% drop in the last hour. The turmoil comes amidst a broader market environment that shows mixed signals, prompting traders to reconsider their positions. With a trading volume of approximately $2.38 million in the last 24 hours, market participants are on high alert for potential shifts.

Market Snapshot

AKT is currently trading at $0.341422 after reaching a 24-hour high of $0.366546 and a low of $0.335036. The asset has seen a decline of 2.25% over the last day, indicating a challenging trading environment. Daily trading volume has reached $2,382,000.59, showcasing a notable level of activity. The market capitalization of AKT now stands at approximately $98,788,402, reflecting its position in the competitive cryptocurrency landscape.

What Could Be Behind This Move

Market observers note that the recent decline in AKT’s price may be reflective of shifting sentiment among traders and potential institutional interest dynamics. Analysts suggest that as the broader cryptocurrency market displays mixed signals, fluctuations in volume and trading activity can significantly influence price action. This particular dip coincides with a notable lack of bullish momentum in related assets, often leading traders to reevaluate their positions in altcoins like AKT.

Institutional Interest Dynamics

Additionally, the recent downturn could indicate waning institutional interest in the Akash Network. As larger players in the crypto space adjust their portfolios, smaller assets like AKT often feel the impact more acutely. On-chain data indicates that while some investors may be accumulating, the overall sentiment appears cautious, with many opting to hold off on significant buys until clearer trends emerge.

Market Sentiment Shifts

Moreover, recent trading activity suggests that traders are increasingly risk-averse in the current market environment. With Bitcoin and Ethereum showing signs of volatility, many altcoins, including AKT, may experience pressure as investors look to safer options. This shift in sentiment can lead to rapid price movements, as seen with the swift 6.85% drop in AKT’s price. Such dynamics underline the importance of monitoring broader market trends as they can dictate the price movements of individual assets.

What Traders Are Watching Next

Moving forward, traders are closely watching key levels for AKT. Support is seen near $0.335036, while the next resistance sits at around $0.366546. A break below the support level could signal further declines, whereas a rebound could prompt renewed interest and buying pressure. As the market continues to evolve, upcoming catalysts or shifts in institutional flow may also impact AKT’s trajectory significantly.

This article is for informational purposes only and does not constitute financial advice. Readers should conduct their own research and consult a financial advisor before making investment decisions.


Sources

  • https://www.coingecko.com/en/coins/akash-network

The post AKT Plunges 6.85% — Is Institutional Interest Waning? appeared first on Coinfomania.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09